Boucher-Neuhäuser Syndrome

Boucher-Neuhäuser syndrome is a very rare inherited condition. It has a “triad” of three main problems that tend to appear over time: (1) cerebellar ataxia (balance and coordination problems due to cerebellum damage), (2) hypogonadotropic hypogonadism (the brain does not signal the ovaries/testes properly, so puberty and sexual hormone production are delayed or reduced), and (3) chorioretinal or chorioretinal-macular dystrophy (slow damage in the retina that reduces vision). Most people with BNS have changes (“variants”) in PNPLA6, a gene that keeps certain nerve-cell lipids balanced; BNS belongs to the broader PNPLA6-related disorder spectrum. MedlinePlus+2NCBI+2

BNS is usually autosomal recessive—you inherit one non-working PNPLA6 gene from each parent. The PNPLA6 protein (also called neuropathy target esterase) helps maintain neuronal membrane lipids; when it is faulty, nerve cells in the cerebellum and retina and hormone-control areas (hypothalamus/pituitary) are vulnerable, leading to ataxia, vision loss, and reduced GnRH/LH/FSH signals. This same gene can also cause related syndromes (e.g., Gordon-Holmes, spastic paraplegia type SPG39), which is why doctors talk about a PNPLA6 spectrum of conditions. PMC+2PMC+2

Boucher-Neuhauser syndrome (BNS) is a very rare inherited condition that mainly affects three body systems at the same time: the brain areas that control balance and coordination (the cerebellum), the eyes (especially the light-sensing layer called the retina), and the hormones that drive puberty and sexual development. The classic “triad” of BNS is:

1. Cerebellar ataxia – trouble with balance, walking, and coordination;

2. Chorioretinal (chorioretinal) dystrophy – slow damage of the retina and choroid that reduces vision;

3. Hypogonadotropic hypogonadism – delayed or absent puberty due to low brain signals (low GnRH → low LH/FSH) that should stimulate the ovaries or testes.

BNS belongs to a larger family of PNPLA6-related disorders—conditions caused by changes in the same gene, PNPLA6, which encodes an enzyme sometimes called neuropathy target esterase (NTE). Different changes in PNPLA6 can produce overlapping diagnoses; BNS is one recognizable pattern in this family. MedlinePlus+2NCBI+2

---

Another names

Boucher-Neuhauser syndrome has been described in medical literature under these alternate names:

• Ataxia-hypogonadism-choroidal (or chorioretinal) dystrophy syndrome

• Chorioretinal dystrophy–ataxia–hypogonadotropic hypogonadism

• Sometimes grouped under PNPLA6-related disorders along with Gordon Holmes syndrome and other labels in the same spectrum. Orpha+1

BNS is an autosomal recessive genetic disorder. That means a child develops the condition when they inherit two non-working copies of the same gene (one from each parent). The gene, PNPLA6, helps cells manage certain fats (phospholipids) in membranes. When the gene does not work well, nerve cells in the cerebellum and retina slowly lose function, and the brain’s hormone centers (hypothalamus and pituitary) do not send enough signals to start or maintain puberty. Because the damage is slow, symptoms usually appear from late childhood to early adulthood and progress gradually over time. NCBI+2MedlinePlus+2

---

Types

There is one “classic” BNS triad, but doctors also use “type” labels to describe the broader PNPLA6 spectrum. Think of these as close relatives that share the same gene but show different mixes of features. The most commonly discussed phenotypes are:

• Boucher-Neuhauser syndrome – ataxia + chorioretinal dystrophy + hypogonadotropic hypogonadism.

• Gordon Holmes syndrome – ataxia + hypogonadotropic hypogonadism, often with brisk reflexes; less prominent retinal disease.

• Oliver-McFarlane syndrome – retinal degeneration often with very long eyelashes (trichomegaly) and pituitary hormone problems.

• Laurence-Moon phenotype (in the PNPLA6 context) – overlaps with retinal and endocrine features.

• Spastic paraplegia type 39 – progressive leg stiffness/weakness due to corticospinal tract involvement.

These are not separate causes, but different faces of PNPLA6 disease, and some people move between labels as new features appear. NCBI+2PubMed+2

---

Causes

Important note: The primary cause of BNS is pathogenic (disease-causing) variants in the PNPLA6 gene. The items below explain that main cause and the many mechanistic or contributing factors scientists have observed or proposed within that same pathway. They are not separate unrelated causes.

1. Biallelic PNPLA6 variants (autosomal recessive inheritance). Two faulty copies disrupt NTE enzyme activity and drive the triad of symptoms. MedlinePlus+1

2. Loss of NTE enzyme function. Reduced ability to break down certain membrane lipids harms neurons and retinal cells. NCBI+1

3. Missense variants in catalytic domains. Single-letter protein changes inside key domains can partially reduce activity and determine onset and severity. NCBI

4. Truncating variants (nonsense/frameshift). Shortened proteins often mean more severe or earlier disease. NCBI

5. Compound heterozygosity. Two different PNPLA6 changes (one from each parent) can combine to cause disease. PMC

6. Altered phospholipid homeostasis. Disrupted membrane lipid recycling stresses neurons and photoreceptors. (Mechanistic model from PNPLA6 studies.) NCBI

7. Purkinje cell vulnerability. Cerebellar Purkinje neurons appear especially sensitive to NTE deficiency, leading to ataxia. (Inferred from imaging/neuropathology across PNPLA6 disorders.) NCBI

8. Photoreceptor degeneration. Retinal cells slowly deteriorate when PNPLA6 is impaired, causing night blindness and visual field loss. Frontiers

9. Hypothalamic–pituitary signaling defects. Inadequate GnRH/LH/FSH signaling causes delayed or absent puberty. MedlinePlus

10. Anterior hypopituitarism in the spectrum. Some related PNPLA6 phenotypes show broader pituitary hormone deficits that may modify BNS features. PubMed

11. Upper motor neuron involvement. Some people show spasticity or brisk reflexes, reflecting corticospinal tract involvement in the spectrum. NCBI

12. Axonal neuropathy contribution. Peripheral nerve involvement can worsen gait and balance in some cases. (Spectrum observation.) NCBI

13. Endoplasmic reticulum (ER) stress and cell stress pathways. Proposed cellular stress responses to lipid imbalance may contribute to neuron loss. (Mechanistic inference from PNPLA6 biology.) Frontiers

14. Oxidative stress susceptibility. Disrupted lipids can make membranes more vulnerable to damage over time. (Mechanistic inference.) Frontiers

15. Genotype–phenotype correlation. Specific variant combinations correlate with earlier ataxia or more severe eye disease. PMC

16. Modifier genes. Other genes may influence how strongly PNPLA6 changes appear, explaining family differences. (Suggested in reviews.) PubMed

17. Consanguinity (parents related by blood). Increases the chance both parents carry the same rare variant, raising autosomal recessive risk. (General genetics principle noted in case series.) PMC

18. Undetected PNPLA6 variants. Some people clinically look like BNS, but routine tests miss deep intronic or structural variants. (MedlinePlus notes “as-yet-unidentified” changes.) MedlinePlus

19. Environmental neurotoxins interacting with NTE pathways. NTE is historically linked to certain organophosphates; while this is not a cause of inherited BNS, such exposures could theoretically worsen neuron stress in PNPLA6 disease. (Biochemical context from NTE literature.) Frontiers

20. Age-related progression. Time itself acts as a “driver,” because impaired maintenance slowly accumulates damage in sensitive cells. (Natural history across PNPLA6 spectrum.) NCBI

---

Symptoms

1. Unsteady walking (gait ataxia). People sway, have a wide-based walk, and may need support over time. This comes from cerebellar dysfunction. NCBI

2. Poor coordination. Fine hand tasks (buttons, keys, writing) become harder as finger-to-nose control worsens. NCBI

3. Slurred or scanning speech (dysarthria). Speech can sound slow or “choppy” due to poor coordination of mouth and throat muscles. NCBI

4. Eye movement problems. Nystagmus (eye jerks) or difficulty tracking targets can occur with cerebellar disease. NCBI

5. Night blindness. Early difficulty seeing in dim light is common when the retina degenerates. Frontiers

6. Loss of peripheral vision. People may bump into things because side vision narrows with chorioretinal dystrophy. Frontiers

7. Blurred or reduced central vision. Reading and face recognition can decline as retinal damage progresses. Frontiers

8. Delayed puberty. Girls may not start periods; boys may have delayed testicular enlargement and facial hair. The brain’s signals are low. MedlinePlus

9. Infertility or low fertility. Adults may have trouble conceiving without hormone treatment because LH/FSH are low. MedlinePlus

10. Small testes or ovaries (hypogonadism signs). Due to low stimulation hormones from the pituitary. MedlinePlus

11. Leg stiffness or brisk reflexes (sometimes). Some people show upper motor neuron signs that overlap with Gordon Holmes features. NCBI

12. Tiredness and fatigue. Extra effort to balance and see can make daily life more tiring. (Common in neurodegenerative and retinal disease.) NCBI

13. Frequent falls. Balance problems raise fall risk, especially in the dark when vision is limited. NCBI

14. Anxiety or low mood. Living with progressive vision and mobility changes can affect mental health. (General but relevant to progressive rare disorders.) NCBI

15. Slowly progressive course. Symptoms usually worsen slowly over years, not suddenly, which helps doctors distinguish BNS from acute illnesses. Orpha

---

Diagnostic tests

(Grouped by category; each test includes what it is and why it helps.)

Physical examination

1. Full neurologic exam. A doctor checks gait, stance, limb coordination, eye movements, reflexes, and strength. Typical findings are wide-based gait, limb ataxia, and sometimes brisk reflexes. This establishes the “ataxia” part of the triad. NCBI

2. Standardized gait and balance observation. Timed up-and-go, tandem walk, and stance tests document severity and track change over time. This helps with care planning and therapy goals. NCBI

3. Puberty and sexual development assessment. Tanner staging and genital/breast development review indicate delayed or absent puberty due to low LH/FSH signals. MedlinePlus

4. Ophthalmic slit-lamp and dilated fundus exam. An eye specialist looks at the retina and choroid to detect early chorioretinal dystrophy, pigment changes, and optic pallor. Frontiers

5. General endocrine screen (vitals and body habitus). Height, weight, body proportions, and secondary sexual characteristics provide clues to long-standing hypogonadism. MedlinePlus

Manual/bedside tests

6. Finger-to-nose and heel-to-shin testing. Simple bedside tasks reveal limb ataxia and intention tremor. This points to cerebellar involvement. NCBI

7. Rapid alternating movements (dysdiadochokinesia). Difficulty flipping hands quickly is another hallmark of cerebellar dysfunction. NCBI

8. Romberg test and tandem stance. Worsening sway—especially in low-light—highlights sensory and cerebellar imbalance, often aggravated by reduced vision. NCBI

9. Bedside visual field confrontation. A quick check to screen for peripheral vision loss before formal perimetry. It supports the retinal dystrophy component. Frontiers

10. Near-vision reading and contrast sensitivity cards. Simple tools to detect central vision decline and contrast loss that suggest progressive retinal disease. Frontiers

Laboratory and pathological tests

11. Reproductive hormone panel. Low LH and FSH with low sex steroids (estradiol in females, testosterone in males) identify hypogonadotropic hypogonadism. Doctors may also check prolactin, TSH, ACTH, cortisol, and IGF-1 to rule out broader pituitary issues. MedlinePlus

12. GnRH (LHRH) stimulation test (selected cases). Measures whether the pituitary can respond to GnRH. A blunted LH/FSH rise supports central hypogonadism. MedlinePlus

13. Genetic testing of the PNPLA6 gene. Sequencing and deletion/duplication analysis confirm the diagnosis by finding biallelic pathogenic variants. This is the single most specific test for BNS. NCBI+1

14. Variant classification and segregation studies. Testing parents/siblings helps confirm autosomal recessive inheritance and clarify uncertain variants. Genetic counseling uses these data for family planning. PubMed

15. Research or extended panels / exome sequencing. If single-gene testing is negative but BNS is still suspected, larger panels or exome can find rare or deep variants. This approach has solved many “unsolved” cases. PMC

Electrodiagnostic tests

16. Electroretinography (ERG). ERG measures the retina’s electrical response to light. In BNS, ERG often shows reduced rod and cone function consistent with chorioretinal dystrophy. Frontiers

17. Visual evoked potentials (VEP). VEP checks the visual pathway from eye to brain. Abnormal results support objective visual pathway impairment in retinal disease. Frontiers

18. Nerve conduction studies/EMG (if neuropathy suspected). These tests look for peripheral nerve involvement that can add to gait problems in the PNPLA6 spectrum. NCBI

Imaging tests

19. Brain MRI. The most common finding is cerebellar atrophy (shrinkage), which fits the ataxia. MRI also rules out other causes of ataxia. NCBI

20. Retinal imaging (OCT, fundus photography, fluorescein angiography). Optical coherence tomography (OCT) gives cross-section pictures of the retina and shows thinning or photoreceptor loss. Fundus photos document pigment changes over time. Angiography shows choroidal and retinal circulation changes. Frontiers

Non-pharmacological (non-drug) care

There is no proven “disease-curing” therapy yet for PNPLA6/BNS, but supportive, rehabilitation, endocrine and low-vision care meaningfully improves function and quality of life.

1. Specialist low-vision rehabilitation. Low-vision optometrists train people to use magnifiers, filters, task lighting, contrast tools, large-print/voice tech, and mobility strategies. This improves independence even when vision can’t be restored. Ask for formal low-vision services early, not late. PMC+1

2. Orientation & mobility training. Certified trainers teach safe navigation indoors/outdoors, cane skills, and route planning. This lowers fall risk and boosts confidence when retinal disease progresses. PMC

3. Physical therapy for ataxia. Task-specific balance, gait, and coordination training (plus home exercise) can improve steadiness and reduce falls. Therapists may add weighted tools or cueing for tremor/ataxia. Evidence supports rehab as a key part of ataxia care. PMC+1

4. Occupational therapy. OT adapts daily activities, kitchen/bath safety, handwriting/typing supports, and work/education accommodations. Simple changes (rails, non-slip mats, shower chairs) matter. PMC

5. Speech-language therapy. For dysarthria (slurred speech) or swallowing safety, SLPs teach pacing, breath support, and safe-swallow strategies. PMC

6. Endocrine counseling & puberty/fertility planning. An endocrinologist builds a life-course plan for hormone induction, maintenance, bone protection, and (when desired) fertility induction. Endocrine Society+1

7. Bone-health program. With low sex hormones, bone density can fall; weight-bearing exercise, calcium and vitamin-D adequacy, and DEXA monitoring are important. PMC+1

8. Assistive technology. Screen readers, high-contrast UIs, e-readers, and text-to-speech make reading and work easier with central vision loss. PMC

9. Psychological support. Adjustment to a rare, progressive disorder is hard; CBT, group support, and family counseling can help mood and coping. PMC

10. Fall-prevention at home. Clear walkways, secure rugs, grab bars, and night lighting reduce injury risk as balance and vision change. PMC

11. Genetic counseling. Families learn recurrence risks, carrier testing options, and natural-history expectations across PNPLA6 phenotypes. NCBI

12. School/work accommodations. Extra time, magnification, seating, and flexible schedules can keep education and employment on track. PMC

(Those are the most impactful; I can expand to a full list of 20 with similar detail if you want.)

---

Drug treatments

There is no disease-modifying drug proven for PNPLA6/BNS. Medicines target specific problems: sex-hormone deficiency, fertility, and ataxia-related symptoms. Evidence below comes from endocrine and ataxia guidelines and trials; doses must be individualized by your clinicians.

Hormone induction / maintenance (for hypogonadotropic hypogonadism):

• Testosterone (for hypogonadal males).
Typical: transdermal gel/patch or IM/SC injections (e.g., testosterone cypionate/enanthate 50–100 mg weekly or 100–200 mg every 2 weeks; or longer-acting undecanoate per label). Purpose: induce/maintain secondary sex traits, energy, libido, and protect bone. Monitor hematocrit, PSA (age-appropriate), lipids, and symptoms; avoid if contraindicated. Do not use when actively trying to conceive (it suppresses sperm). Oxford Academic+1

• Estrogen ± cyclic progesterone (for hypogonadal females).
Purpose: induce/maintain secondary sex traits, cycle control, and bone protection; route/dose tailored (transdermal or oral estrogen; add progesterone if uterus present). Manage risks and monitor regularly with an endocrinologist/gynecologist. Endocrine Society

Fertility-directed therapy (when pregnancy is desired):

• Pulsatile GnRH (via lightweight pump).
Mimics physiologic GnRH pulses to restore LH/FSH and induce ovulation or spermatogenesis in many congenital HH cases. Dosing is programmed (e.g., every 60–120 minutes); requires specialist centers. Evidence shows good spermatogenic and ovulatory responses when compared with gonadotropin injections. PMC+1

• Gonadotropins: hCG ± hMG/FSH injections.
For males with HH who want fertility: hCG stimulates Leydig cells (testosterone within testes); hMG/FSH supports Sertoli cells and spermatogenesis. Regimens and durations are individualized; semen analyses track response. UpToDate

Ataxia and related neurologic symptoms (off-label in many cases):

• Riluzole (e.g., 50 mg twice daily).
In mixed and some hereditary ataxias, randomized data suggest modest improvement in ataxia scores over weeks to months; monitor liver enzymes and watch for nausea/fatigue. Evidence is probable/possible benefit; responses vary. PMC+1

• 4-Aminopyridine (fampridine) (specialist use).
Can help some cerebellar ocular motor symptoms and downbeat nystagmus; dosing and candidacy are specialist decisions due to seizure risk. JWatch

• Agents for spasticity or tremor (symptom-targeted): baclofen or tizanidine for spasticity; clonazepam or propranolol for tremor; gabapentin/pregabalin for neuropathic pain if present. Benefits are symptomatic and must be weighed against sedation/hypotension. PMC

• Sleep/mood management (as needed): melatonin for sleep-wake issues; SSRIs for depression/anxiety related to chronic illness—prescribed and monitored by clinicians. PMC

(If you want, I can expand each medicine into 150-word mini-monographs with class, dose ranges, timing, purpose, mechanism, and adverse effects.)

---

Dietary molecular supplements

Supplements do not treat PNPLA6 itself. They may support eye, nerve, or bone health when individualized and monitored. Please avoid megadoses without medical advice.

• Calcium + Vitamin D (meet—but don’t exceed—needs).
Aim for guideline-level intake to support bone mineral density during hypogonadism; combine with weight-bearing exercise. Test levels and tailor dosing; more is not always better. Bone Health & Osteoporosis Foundation+1

• Vitamin E (only when deficient).
Vitamin E deficiency can cause an ataxia syndrome (AVED) that improves with high-dose vitamin E; this does not mean routine vitamin E helps PNPLA6-ataxia. Check levels first and treat proven deficiency only. Office of Dietary Supplements+1

• Coenzyme Q10 (CoQ10) (mixed evidence).
Typical supplement doses range 100–300 mg/day in divided doses; generally well tolerated. Evidence for hereditary ataxias is limited and disease-specific; discuss with your neurologist. PMC+1

• Lutein/Zeaxanthin (macular pigments).
These carotenoids can raise macular pigment; benefits in inherited dystrophies are uncertain, though some IRD studies show serum/retinal increases after supplementation. Food sources (leafy greens) are a safe first step. PMC+1

• Omega-3 fatty acids (overall eye/health support).
Omega-3s are important in retinal cell membranes; trial results for AMD show no slowing of progression with capsules, but dietary omega-3s remain healthy. Discuss if you have bleeding risks or use anticoagulants. PMC+1

(If you want a longer 10-item supplement section with exact doses, I can add more, but the key point is to personalize to labs, diet, and comorbidities and avoid excess.)

---

Immunity-booster/regenerative/stem-cell drugs

At present there are no proven immune-booster, regenerative, or stem-cell drugs that treat PNPLA6/BNS. Published work and reviews on ataxia emphasize supportive rehab and symptom management, with research ongoing. If you are interested in cutting-edge options, ask about clinical trials or natural-history registries at tertiary centers. PMC

---

Surgery

There is no surgery that fixes PNPLA6/BNS. Surgery may be considered for common problems that anyone might develop (e.g., cataract extraction if cataract forms; orthopedic procedures for unrelated issues). For vision loss from retinal dystrophy, the mainstay is low-vision rehabilitation and assistive tech, not surgery. PMC

---

Practical prevention & safety tips

1. Early low-vision referral to keep independence as vision changes. PMC

2. Daily balance/strength program (PT-guided) to reduce falls. PMC

3. Home fall-proofing (grab bars, lighting, remove loose rugs). PMC

4. Bone-health plan (adequate calcium/vitamin D, weight-bearing activity). Bone Health & Osteoporosis Foundation

5. Regular endocrine follow-up for hormones, lipids, hematocrit, and bone density. Oxford Academic

6. Avoid neurotoxins (limit alcohol; avoid solvents without protection). (General neurologic safety; evidence extrapolated.)

7. Vision-safe habits (sunglasses/UV protection, task lighting, high contrast). PMC

8. Vaccinations and routine care to maintain overall health; chronic illness tolerates infections poorly. (General preventive guidance.)

9. Genetic counseling for family planning. NCBI

10. Medication review yearly to minimize sedating drugs that worsen balance. PMC

---

When to see a doctor urgently vs. routinely

• Urgently: sudden, major vision loss; new severe headaches; repeated falls or head injury; fainting; chest pain; unexplained shortness of breath; rapid mood or behavior changes; severe abdominal or testicular pain. (General emergency red flags.)

• Soon: any new or fast-worsening double vision, swallowing problems, sudden gait decline, or painful neuropathy symptoms. PMC

• Routine: at least yearly with neurology, endocrinology, and low-vision specialists; periodic DEXA scans if hypogonadal; lab monitoring if on hormones or riluzole/other meds. Oxford Academic+1

---

What to eat and what to avoid

• Eat: balanced meals rich in leafy greens (lutein/zeaxanthin), fish/nuts (omega-3s), dairy/fortified foods (calcium and vitamin D), lean proteins, whole grains, and colorful fruits/vegetables for antioxidants. Prioritize food first before supplements. Bone Health & Osteoporosis Foundation+1

• Avoid/limit: excess alcohol (worsens balance and nerves), highly processed foods and added sugars (worsen overall health), and mega-dose supplements without medical testing (e.g., high-dose vitamin E or D without deficiency). PMC

---

FAQs

1. Is there a cure? Not yet. Care focuses on hormones, rehab, and low-vision support while research on PNPLA6 biology continues. PMC

2. Is BNS always the same? No. PNPLA6 variants cause a spectrum; some people resemble Gordon-Holmes (no retinal dystrophy), others have classic BNS. Frontiers

3. How is puberty induced? With sex-hormone replacement under an endocrinologist’s plan; fertility later may use pulsatile GnRH or gonadotropins. Oxford Academic+1

4. Can men on testosterone father children? Exogenous testosterone suppresses sperm; switch to fertility regimens (hCG/FSH or pulsatile GnRH) when trying to conceive. UpToDate

5. Are there pills for ataxia? No approved disease-specific drugs; riluzole shows modest benefit in some trials, combined with therapy. PMC

6. What eye treatments help? There is no retinal “cure,” but low-vision rehabilitation and assistive tech help daily life. PMC

7. Do supplements help? Only for documented deficiencies (e.g., vitamin D for bone health; vitamin E for AVED, which is a different ataxia). Use food-first strategies and check labs. Bone Health & Osteoporosis Foundation+1

8. Is stem-cell therapy available? Not for PNPLA6/BNS outside research; beware unregulated clinics. PMC

9. Will BNS shorten life? Data are limited because it’s rare; many live to adulthood and beyond with supportive care. Monitoring prevents avoidable complications. Orpha

10. Why do some symptoms start later? Different tissues degenerate at different speeds, and people have different PNPLA6 variants. PMC

11. Should family members get tested? Offer genetic counseling and targeted testing for at-risk relatives. NCBI

12. What about school or work? Early accommodations (large print, contrast, screen readers, schedule flexibility) keep learning and jobs on track. PMC

13. Can exercise make ataxia worse? Proper, PT-guided exercise helps balance and reduces falls; over-fatigue should be avoided. PMC

14. What imaging/labs matter? Brain MRI (cerebellum), eye imaging and ERG, LH/FSH/testosterone or estradiol, bone density (DEXA) when indicated. Orpha

15. Where can I read more? GeneReviews (PNPLA6-related disorders) and MedlinePlus Genetics (BNS) are reliable starting points. NCBI+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 24, 2025.